The Title X Network Has Largely Returned Under the Biden Administration May 25, 2023 News Release A new KFF brief examines the return of grantees and clinic sites to the Title X network under the Biden Administration, which reversed Trump Administration regulations that prohibited Title X sites from providing abortion referrals and having co-located abortion services. For more than 50 years, the federal Title X program…
Rebuilding the Title X Network Under the Biden Administration May 25, 2023 Issue Brief This issue brief examines what has happened to the Title X network under the Biden Administration regulations, including the number of clinics that have returned to the network, new funding, and how state policies that prohibit pregnancy options counseling that includes abortion and referrals may impact grantees’ participation in the Title X program.
What Are the Exceptions to State Abortion Bans? May 18, 2023 News Release A new KFF analysis reviews exceptions to abortion bans and describes how the stated aim to provide life-saving and health-preserving abortion care may not be achieved in practice. Abortion is currently banned in 14 states and many other states have attempted to ban or severely restrict abortion access. Exceptions to…
Explaining Litigation Challenging the ACA’s Preventive Services Requirements: Braidwood Management Inc. v. Becerra May 15, 2023 Issue Brief This brief explains the preventive services coverage requirements, the basis of the Braidwood Management Inc. v. Becerra lawsuit, next steps in the litigation, and the potential implications.
Update on the Status of Medication Abortion and the Courts April 21, 2023 Blog This policy watch explains the April 21, 2023 United States Supreme Court’s ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA’s approval of mifepristone, the medication abortion pill.
Q & A: Implications of Two Conflicting Federal Court Rulings on the Availability of Medication Abortion and the FDA’s Authority to Regulate Drugs April 8, 2023 Blog This policy watch explains the two conflicting rulings on the provision of mifepristone issued by two separate District Courts on April 7, 2023, Alliance for Hippocratic Medicine v. FDA and State of Washington v. United States Food and Drug Administration.
After Dobbs, Survey Seeks to Understand Telecontraception Clients Better April 4, 2023 News Release According to a new KFF survey with a nonprobability sample of clients from four online sources of contraception, one in four clients said they got emergency contraception to have on hand because of the Supreme Court’s decision to overturn Roe v. Wade. Additionally, more than a fifth (22%) said they…
Who Uses Telecontraception and Why? A Closer Look at Clients of Four Telecontraception Companies April 4, 2023 Issue Brief Based on the findings of a nonprobability sample of 6,000 survey respondents from four telecontraception companies, this brief presents a snapshot of telecontraception users and their reasons for using these platforms.
As the Courts Weigh the Future of the ACA’s Preventive Services Coverage, a New Analysis Shows that Most People with Private Insurance Received At Least One of Those Benefits in 2018 March 20, 2023 News Release The provision of the Affordable Care Act (ACA) that requires most private health plans to cover many preventive services without any cost-sharing for their enrollees is being challenged in federal court. The U.S. District Court in the Northern District of Texas in September concluded that aspects of the requirement were…
Challenges to the FDA’s Approval of Medication Abortion Pills Could Curtail Access Throughout the United States March 14, 2023 News Release In anticipation of a ruling in a case with enormous implications for access to medication abortion in the United States, a new KFF brief explains the impact of this case, and others filed in federal courts, involving the FDA’s regulation of medication abortion. The case that has gotten the most…